Clinical Trial Detail

NCT ID NCT03425331
Title Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

non-small cell lung carcinoma

Therapies

Nivolumab + Ipilimumab

Age Groups: adult senior

Additional content available in CKB BOOST